Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Jul 14, 2013; 19(26): 4119-4126
Published online Jul 14, 2013. doi: 10.3748/wjg.v19.i26.4119
Published online Jul 14, 2013. doi: 10.3748/wjg.v19.i26.4119
Epithelial toll-like receptor 9 signaling in colorectal inflammation and cancer: Clinico-pathogenic aspects
István Fűri, Ferenc Sipos, Alexandra Kalmár, Györgyi Műzes, 2nd Department of Internal Medicine, Semmelweis University, 1088 Budapest, Hungary
Tiana M Germann, Faculty of Medicine, Semmelweis University, 1086 Budapest, Hungary
Zsolt Tulassay, Béla Molnár, Molecular Medicine Research Unit, Hungarian Academy of Sciences, 1051 Budapest, Hungary
Author contributions: Fűri I, Sipos F and Műzes G contributed to the writing and editing of the manuscript; Germann TM and Kalmár A contributed in figure composing and language editing; Tulassay Z and Molnár B revised the text.
Correspondence to: Ferenc Sipos MD, PhD, 2nd Department of Internal Medicine, Semmelweis University, Szentkirályi str. 46., 1088 Budapest, Hungary. dr.siposf@gmail.com
Telephone: +36-20-4780752 Fax: +36-1-2660816
Received: January 19, 2013
Revised: April 23, 2013
Accepted: April 28, 2013
Published online: July 14, 2013
Revised: April 23, 2013
Accepted: April 28, 2013
Published online: July 14, 2013
Core Tip
Core tip: Toll-like receptor 9 mediated signaling influences and regulates the severity of mucosal inflammation, and seems to have a protective role against malignant transformation. The modulation of toll-like receptor 9 signaling by synthetic oligodeoxynucleotide agonists or antagonists seems to have beneficial therapeutic effect in inflammatory and cancerous colonic disorders.